

# Greenwich Clinical Matters



South East London  
Clinical Commissioning Group

## MEDICINES MANAGEMENT

### Fexofenadine hydrochloride 120 mg tablets now available over the counter

NHSE guidance states treatment of mild to moderate hay fever/seasonal rhinitis will not routinely be offered in primary care but can be bought over the counter.

Fexofenadine 120 mg tablets are now available to purchase over the counter for adults and children 12 years and older, for the relief of symptoms associated with seasonal allergic rhinitis. This advice does not apply to fexofenadine for the management of urticaria or when used in an off-label manner. Practices may use this opportunity to refer patients via the GP Community Pharmacy Consultation service (GP CPCS) with either minor ailments or self-limiting conditions to community pharmacists, so patient get seen by the correct health care professional. Please note that the GP CPCS forms part of the – Investment and Impact Fund (IIF) for 2022-23. For further information [click here](#)

**Action:** Patients requesting fexofenadine 120mg tablets for mild to moderate hay fever/seasonal rhinitis should be directed to self-care and GP CPCS where appropriate.

For GP CPCS Practices need to activate their generic email with EMIS health so that they can receive notification from Pharmoutcomes.

### FP34 form submission

GPs who want to make a claim for certain high-volume personally administered vaccines, must make them on an FP34 appendix form.

**Action:** Practices are advised to submit their claims month to avoid their payments being deducted in the following financial year.

### Online diabetes courses

Free PITstop live courses available offering accredited diabetes training are available to any appropriate healthcare professionals who work within Bexley, Greenwich, and Lewisham.

**Action:** Please find attachment 1.0 the updated PITstop training course flyer for further information.

### Cardiovascular disease webinars

#### Practical tips for primary care to support the CVD DES incentives this year:

By Cardiovascular Pharmacists for South East London: 16<sup>th</sup> May 2022 1-2pm

**Action:** For further information and registration [click here](#)

#### South East England lipid management webinar:

To support Implementation of the latest NICE approved Lipid Management Pathway: 5<sup>th</sup> May 2022 10am-1pm:

**Action:** For further information and registration, [click here](#)

## MEDICINES MANAGEMENT

### Drug Safety Update Inadvertent Oral Administration of Potassium Permanganate

Potassium permanganate is supplied in concentrated forms, either as a 'tablet' or a solution, which requires dilution before use. These concentrated forms resemble an oral tablet or drink and if ingested are highly toxic

**Action:** For further information [click here](#)

### [Amiodarone \(Cordarone X\): reminder of risks of treatment and need for patient monitoring and supervision](#)

Amiodarone has been associated with serious and potentially life-threatening side effects, particularly of the lung, liver, and thyroid gland.

**Action:** Patients should be supervised and reviewed regularly during treatment.

### [Metformin in pregnancy: study shows no safety concerns](#)

The licence for metformin now reflects that it can be considered for use during pregnancy and the periconceptional phase as an addition or an alternative to insulin, if clinically needed.

### [Joint statement: Access to flash glucose monitors and continuous glucose monitors](#)

The NHS London Procurement Partnership and London Diabetes Clinical Network following the update publications of the [NICE guideline on Type 2 diabetes in adults: management](#), and the [NICE guideline on Type 1 diabetes in adults: diagnosis and management](#), which addresses access to flash glucose monitors and continuous glucose monitors (CGM) have issued a joint statement (see attachment 2.0).

The guidance recommends that:

- all adults with type 1 diabetes should have access to either Flash or CGM
- all children with type 1 diabetes should have access to CGM
- some people with type 2 diabetes who use insulin intensive therapy (2 or more injections a day) should have access to Flash, for example if they experience recurrent or severe hypos, if they have a disability that means they cannot finger-prick test or if they would otherwise be advised to test 8 or more times a day.

Further advice to help address variability in access and provision to Flash and CGM will be coming out soon.

**Action:** Initiation of flash glucose monitoring should continue through specialist clinic and transferred to primary care using transfer of care form, for approved conditions as per [SEL joint formulary](#).

## MEDICINES MANAGEMENT

### Out of Stock Update

#### Sandrena 500microgram or 1mg gel in single dose sachet:

There may be difficulty in obtaining supplies though still available.

**Action:** Contact customer care on 01635520300 for advice on wholesale suppliers.

**Lenzetto 1.53mg/spray transdermal spray solution:** There is a temporary shortage in supply of the x1 pack, supplies expected sometime in April 2022.

**Action:** The x3 pack remains in full supply.

**Oestrogel 0.006% gel:** Besins Healthcare (UK) Ltd expects this to be a short-term issue and anticipates that supplies will be available to local wholesaler branches soon.

**Action for HRT preparation:** Prescribers should consider using equivalent preparations to those that their patients are currently using. For further information see link below ([Click here for HRT preparations and equivalent](#)) ([Click here for practical prescribing](#)).

#### Oxybutynin transdermal patch 3.9mg/24hours (Kentera)

Restricted to use in patients unable to tolerate oral medication only. Anticipated re-supply date 31/05/2022.

**Action:** Defer initiating new patients on the transdermal patch until supply issue resolves. Review patients currently on treatment, consider switching to oxybutynin tablets or oral solution. For further information [click here](#)

### CQC Inspection Searches

Ardens has been selected as the approved provider of CQC searches to support GP practices with their CQC inspection. During an initial 12-month pilot, Ardens will be supporting CQC in delivering their clinical searches to make the CQC inspection process as seamless and effortless as possible for practices and to enable an open and transparent regulatory process.

Searches will be made available for all GP practices (including non-subscribers) free of charge from May 2022.

**Action:** For more information, please visit [www.ardens.org.uk/cqc/](http://www.ardens.org.uk/cqc/)

## SYSTEM DEVELOPMENT: DIABETES

### Diabetes Book & Learn survey

The diabetes commissioners from across South London wish to seek feedback on Diabetes Book & Learn from staff who refer patients to the service for diabetes structured education.

#### Action:

- Please share this survey with those people who make referrals to the service from within your practice, this may be multiple staff members. This survey will take less than 5 minutes to complete.
- To ensure your comments are recorded please **complete this survey by 6pm on Tuesday 19th of April** and please also remember to complete the survey via <https://www.surveymonkey.co.uk/r/LJXKC3D>

## MEDICINES MANAGEMENT

### SEL Integrated Medicines Optimisation Committee (IMOC)

The following IMOC decisions/outputs are now available and can be accessed via the links:

#### NEW

- [Formulary inclusion](#) of Xonvea™ (doxylamine succinate 10mg/pyridoxine hydrochloride 10mg gastro-resistant tablets) for treatment of nausea and vomiting in pregnancy as **amber 2** (*initiation and first prescription from the specialist team*). Certain criteria apply for use of Xonvea™ – please refer to the [formulary recommendation](#) for further details.

#### UPDATED

- [Formulary recommendation 092](#) for intrauterine delivery systems - Levosert® and Kyleena® has been updated to include the new licensing for Levosert® - duration of use updated to six years. Please refer to the [formulary recommendation](#) for further detail.
- [Hypertension Guidance for Primary Care in SEL](#) has been updated through the Cardiovascular subgroup of the SEL IMOC. Updates include clarifications to the traffic light system and inclusion of lifestyle interventions.
- [The SEL Rheumatoid Arthritis Drug Treatment Pathway](#) has been updated through the Rheumatology subgroup of the SEL IMOC. Updates include inclusion of upadacitinib in line with NICE as a second line biologic option for the management of moderate rheumatoid arthritis.
- The [SEL Seronegative Spondyloarthritis Drug Treatment Pathway](#) has been updated through the Rheumatology subgroup of the SEL IMOC. Updates include inclusion of upadacitinib in line with NICE as a second line biologic option for the management of psoriatic arthritis (PsA) and the use of dose escalated guselkumab within a locally agreed criteria for the management of severe PsA.
- The [SEL Inflammatory Bowel Disease \(IBD\) and iron deficiency in IBD pathway](#) has been updated through the IBD subgroup of the SEL IMOC. Updates include primary care initiation of Entocort® (budesonide MR) for the management of mild to moderate ileocaecal Crohn's disease (CD) and the use of [dose escalated anti-TNF therapy](#) and [dual biologic therapy](#) within a locally agreed criteria for the management of severe CD
- The [Home medicines and first aid kit patient information leaflet \(COVID edition\)](#) has been updated to continue supporting patients who may isolate at home when infected with COVID-19.
- The [Sativex® for the treatment of spasticity associated with multiple sclerosis in adults shared care guideline](#) has been updated to include revised contact details within the communication and support section.

## Contact Details

**Meds Management:** [greccg.pharmacy@nhs.net](mailto:greccg.pharmacy@nhs.net) (020 3049 9000)

**Primary Care:** Jan Matthews: [jan.matthews@nhs.net](mailto:jan.matthews@nhs.net)

**System Development:** Jo Hare: [joannehare@nhs.net](mailto:joannehare@nhs.net)